pharmaceutical industry
The Latest
-
Regeneron Shares Dip Amid $1.1 Billion Cancer Drug Deal
Regeneron's shares dropped by 4.3% to 630.70 per share after it announced its $1.1 billion deal with Sanofi. 
Regeneron's shares dropped by 4.3% to 630.70 per share after it announced its $1.1 billion deal with Sanofi. -
Shanghai Green Valley To Being U.S. Trials Of Promising New Alzheimer's Drug
Shanghai Green Valley plans to sign up for 2,046 test subjects for its trials across the U.S. 
Shanghai Green Valley plans to sign up for 2,046 test subjects for its trials across the U.S. -
Takeda Pharmaceutical Commits To China Expansion
Takeda Pharmaceutical has spent more than 1.5 billion yuan over the past five years to build its business in China. 
Takeda Pharmaceutical has spent more than 1.5 billion yuan over the past five years to build its business in China. -
Johnson & Johnson Buying Momenta Pharmaceuticals For $6.5 Billion In Cash
Momenta deal will enhance Johnson & Johnson unit’s lead in autoimmune diseases, it says. 
Momenta deal will enhance Johnson & Johnson unit’s lead in autoimmune diseases, it says. -
Kodak Shares Nearly Quadruple After Landing $765 Government Loan
Kodak's stock prices went from $2.62 per share on Monday to a high of $10.94 per share on Tuesday. 
Kodak's stock prices went from $2.62 per share on Monday to a high of $10.94 per share on Tuesday. -
Shanghai Fosun Pharmaceutical Shares Surge After Beijing Approves Vaccine Trials
The National Medical Products Administration (NMPA) has approved Fosun Pharmaceutical's clinical trial application for its Covid-19 mRNA vaccine candidate. 
The National Medical Products Administration (NMPA) has approved Fosun Pharmaceutical's clinical trial application for its Covid-19 mRNA vaccine candidate. -
Boehringer Ingelheim To Establish First Overseas Branch In China
The German pharmaceutical giant plans to invest up to 23.55 million yuan to set up its first overseas BI X digital laboratory in Shanghai. 
The German pharmaceutical giant plans to invest up to 23.55 million yuan to set up its first overseas BI X digital laboratory in Shanghai. -
India Expects Price Increases On Generic Drugs Due To Supply Chain Forecasts
India's pharmaceutical companies revealed that although there is a sufficient supply of APIs until April, price increases for generic drugs are expected after the period due to supply chain disruptions in China. 
India's pharmaceutical companies revealed that although there is a sufficient supply of APIs until April, price increases for generic drugs are expected after the period due to supply chain disruptions in China. -
Merck To Spin-Off Businesses To Focus More On Growth Drivers
Merck & Co will be spinning off its other businesses, including its women's health and biosimilar drug units, into separate publicly-listed companies. 
Merck & Co will be spinning off its other businesses, including its women's health and biosimilar drug units, into separate publicly-listed companies. -
Merck Buys Drug Producer ArQule In $2.7 Billion Cash Deal
Merck will be purchasing cancer drug maker ArQule for $20 per share in an all-cash deal estimated to be worth around $2.7 billion. 
Merck will be purchasing cancer drug maker ArQule for $20 per share in an all-cash deal estimated to be worth around $2.7 billion.
